

Tumor Antigen by Immunoassay CA 19-9 (86301) – NCD 190.30

Indications:
Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.
Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma. The test is not indicated for diagnosing these two diseases.

Limitations:
These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient’s response to treatment with subsequent treatment cycles.

Most Common Diagnoses (which meet medical necessity) *	
C22.1	Intrahepatic bile duct carcinoma
C23	Malignant neoplasm of gallbladder
C24.0	Malignant neoplasm of extrahepatic bile duct
C24.1	Malignant neoplasm of ampulla of vater
C24.9	Malignant neoplasm of biliary tract
C25.0 through C25.9	Malignant neoplasm of all parts of the pancreas
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.89	Secondary malignant neoplasm of other digestive organs
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
D37.9	Neoplasm of uncertain behavior of digestive organ
G89.3	Neoplasm related pain
R97.8	Other abnormal tumor markers
Z85.07	Personal history of malignant neoplasm of pancreas
Z85.09	Personal history of malignant neoplasm of other digestive organs

*For the full list of diagnoses that meet medical necessity see the Tumor Antigen by Immunoassay CA19-9 National Coverage Determination 190.30 document

The above CMS and WPS-GHA guidelines are current as of: 1/01/2024.